Zika virus (ZIKV) infection during pregnancy has emerged as a global public health problem because of its ability to cause severe congenital disease. Here, we developed six mouse monoclonal antibodies (mAbs) against ZIKV including four (ZV-48, ZV-54, ZV-64, and ZV-67) that were ZIKV specific and neutralized infection of African, Asian, and American strains to varying degrees. X-ray crystallographic and competition binding analyses of Fab fragments and scFvs defined three spatially distinct epitopes in DIII of the envelope protein corresponding to the lateral ridge (ZV-54 and ZV-67), C-C' loop (ZV-48 and ZV-64), and ABDE sheet (ZV-2) regions. In vivo passive transfer studies revealed protective activity of DIII-lateral ridge specific neutralizing mAbs in a mouse model of ZIKV infection. Our results suggest that DIII is targeted by multiple type-specific antibodies with distinct neutralizing activity, which provides a path for developing prophylactic antibodies for use in pregnancy or designing epitope-specific vaccines against ZIKV.
In Brief
A panel of Zika virus-specific monoclonal antibodies are developed that can neutralize infection of the African, Asian, and American strains. Of these, antibodies that target the lateral ridge epitope in the DIII region of the viral E protein can confer in vivo protection in an animal model of infection and may represent a path for development of prophylactic or therapeutic antibodies in pregnancy or vaccines against Zika virus. Accession Numbers 5KVD 5KVE 5KVF 5KVG
INTRODUCTION
Zika virus (ZIKV), a flavivirus transmitted by Aedes species mosquitoes, was originally identified in 1947 from a sentinel rhesus monkey in the Zika forest of Uganda (Dick, 1952; Dick et al., 1952) . It is closely related to the four serotypes of dengue (DENV) as well as other globally relevant viruses including yellow fever (YFV), West Nile (WNV), and Japanese encephalitis (JEV) viruses . Since its identification almost 70 years ago, there were few studies of ZIKV until this past year, when large epidemics in the Americas were accompanied by unexpectedly severe clinical manifestations. Although in most instances ZIKV infection results in a mild febrile illness associated with rash and conjunctivitis, severe neurological phenotypes have been described including Guillain-Barré syndrome and meningoencephalitis (Carteaux et al., 2016; Oehler et al., 2014) . Infection in pregnant women (Brasil et al., 2016) and mice (Cugola et al., 2016; Li et al., 2016; Miner et al., 2016 ) is now linked causally to fetal abnormalities including microcephaly, spontaneous abortion, and intrauterine growth restriction due to placental insufficiency.
Like other flaviviruses, ZIKV is a positive-sense RNA virus with an $11-kilobase open reading frame flanked by 5 0 and 3 0 non-coding regions. The genome encodes a single polyprotein that is post-translationally cleaved by host and viral proteases into three structural proteins (capsid [C] , pre-membrane [prM] , and envelope [E] ) and seven non-structural proteins. C forms a nucleocapsid when bound to viral RNA; prM complexes with E shortly after synthesis to facilitate folding and prevent premature fusion to host membranes; and E mediates viral assembly, attachment, entry, and fusion. The ZIKV E protein is divided into three domains: a central b-barrel domain (domain I [DI] ), an extended dimerization domain (DII), and an immunoglobulin-like segment (DIII) (Dai et al., 2016) . The distal end of DII contains the fusion loop (FL), a hydrophobic sequence that inserts into the host cell endosomal membrane during pH-dependent conformational changes that drive fusion. Two high-resolution cryoelectron microscopic structures show that, like other flaviviruses, mature ZIKV virions are smooth particles that incorporate 180 copies each of the E and cleaved M proteins (Kostyuchenko et al., 2016; Sirohi et al., 2016) . As in DENV (Kuhn et al., 2002) , the E proteins of ZIKV pack as antiparallel dimers in a herringbone pattern that lie relatively flat against the lipid envelope.
Neutralizing antibodies have important roles in the protection against infection by many flaviviruses and are considered correlates of protection for licensed YFV and tick-borne encephalitis virus (TBEV) vaccines (Belmusto-Worn et al., 2005; Heinz et al., 2007) . The E protein is a primary antigenic target of neutralizing antibodies, which bind epitopes in all three structural domains, with many type-specific protective antibodies recognizing determinants in DIII (Beasley and Barrett, 2002; Oliphant et al., 2005; Shrestha et al., 2010; Sukupolvi-Petty et al., 2010) . Potently neutralizing anti-flavivirus antibodies also recognize complex quaternary epitopes composed of more than one domain or E protein (de Alwis et al., 2012; Kaufmann et al., 2010; Rouvinski et al., 2015) . In comparison, antibodies that recognize the fusion loop in DII are more cross-reactive and neutralize flaviviruses less efficiently, although they may still have protective activity in vivo (Cherrier et al., 2009; Dai et al., 2016; Vogt et al., 2011) .
In this study, we developed six mouse monoclonal antibodies (mAbs) against ZIKV after immunizing with live virus and boosting with infectious virus or recombinant E proteins. Four of the mAbs (ZV-48, ZV-54, ZV-64, and ZV-67) neutralized infection of African, Asian, and American strains of ZIKV to varying degrees, whereas two (ZV-2 and ZV-13) inhibited infection poorly. High-resolution crystal structures were determined for three Fabs and one single-chain variable fragment (scFv) bound to DIII, defining three non-overlapping conformational epitopes: the lateral ridge (LR) (ZV-54 and ZV-67), the C-C 0 loop (ZV-48 and ZV-64), and the ABDE sheet (ZV-2). In vivo passive transfer studies in a lethal mouse model of ZIKV infection revealed protective activity of neutralizing DIII LR mAbs. Overall, our results suggest that DIII is targeted by several different type-specific antibodies with distinct neutralizing activities.
RESULTS

Generation of mAbs against ZIKV E Protein
To generate a panel of antibodies against ZIKV, we serially infected Irf3 À/À mice 30 days apart with ZIKV MR-766 (Uganda, 1947) and ZIKV H/PF/2013 (French Polynesia, 2013 . Irf3
mice were used instead of wild-type (WT) mice, because ZIKV strains are deficient in evading type I interferon-mediated immunity Rossi et al., 2016) . 3 days before myeloma-splenocyte fusion, mice were boosted intravenously with ZIKV H/PF/2013 or recombinant DIII (amino acids 299 to 407 of the ZIKV E protein). After screening $2,000 hybridomas, we isolated six mAbs that recognized ZIKV E protein by ELISA (Table 1) . We tested the mAbs for their specificity by evaluating reactivity with cells infected by ZIKV, DENV (all four serotypes), or JEV. Five of the mAbs (ZV-2, ZV-48, ZV-54, ZV-64, and ZV-67) were ZIKV specific and did not recognize DENV-or JEV-infected cells by flow cytometry ( Figure 1A ; data not shown); these mAbs all bound to recombinant ZIKV DIII in a direct ELISA ( Figure 1B ). In contrast, ZV-13 was cross-reactive and bound to cells infected with all serotypes of DENV ( Figure 1A ). Consistent with these data, only ZV-13 bound to WNV E protein, as detected by ELISA ( Figure 1B ). ZV-13 recognized the conserved FL in DII, as binding was lost to a ZIKV E protein with mutations in highly conserved residues within and immediately proximal to the FL ( Figure 1B ).
Neutralizing Activity against ZIKV In Vitro
We evaluated the mAbs for their ability to inhibit ZIKV H/PF/2013 infection. Four (ZV-48, ZV-54, ZV-64, and ZV-67) of the six mAbs had neutralizing activity, whereas two (ZV-2 and ZV-13) did not inhibit infection appreciably ( Figure 1C ). To determine the breadth of their activity, the mAbs were evaluated for inhibition of infection by three other ZIKV isolates including two African (MR-766, Uganda, 1947 and Dakar 41519, Senegal, 1982) and an American (Paraiba, Brazil, 2015) strain. Whereas ZV-54 and ZV-67 neutralized all four ZIKV strains, ZV-48 and ZV-64 had reduced inhibitory activity against the other tested strains (Figure 1C ; Table 1 ).
Binding Characteristics of Anti-ZIKV mAbs We next assessed whether the variation in neutralizing activity among our antibodies could be explained by differences in binding to the ZIKV E protein derived from H/PF/2013. Based on the ELISA data ( Figure 1B) , we tested the mAbs for binding to a recombinant DIII produced in E. coli using biolayer interferometry (BLI) ( Figure 2A ; Table 1 ) or, for the fusion-loop epitope binding ZV-13, the monomeric form of the ectodomain of E expressed in mammalian cells ( Figure S1 ; Table 1 ). These biophysical analyses showed that mAbs with stronger neutralizing capacity had greater binding affinities for recombinant proteins. The best neutralizing antibodies, ZV-54 and ZV-67, had the highest affinities with K D equilibrium values less than 10 nM. These two mAbs also showed the slowest dissociation rates, with half-lives of 33 and 13.8 min, respectively. binding to the viral particle, which also is a function of epitope accessibility (Pierson et al., 2007) , might correlate with our neutralization data. To test this idea, we captured purified ZIKV subviral particles (SVPs, prM-E) on 96-well plates and analyzed binding of biotinylated detection mAbs over a range of concentrations. There was an association between the functional avidity of binding and the ability to neutralize infection: ZV-67 and ZV-54 bound more avidly than did ZV-2 and ZV-13 ( Figure 2B ). These data also showed that even at the highest concentrations tested, ZV-2 and ZV-13 failed to saturate binding to the SVPs. We confirmed these results with pseudo-infectious reporter virus particles (RVPs) in a functional assay. Antibody-mediated neutralization requires engagement of the virions by antibody with a stoichiometry sufficient for neutralization. Antibodydependent enhancement of infection (ADE) occurs following engagement of the virion by fewer antibody molecules and thus represents a sensitive functional probe for antibody binding to an infectious virion. We evaluated the antibody concentration dependence and magnitude of ADE of ZIKV and DENV by our anti-ZIKV mAbs using an established assay (Pierson et al., 2007) in Fcg receptor II (FcgRII, CD32A) expressing human K562 cells. While all ZIKV mAbs enhanced infection to varying degrees, those which bound SVPs weakly (e.g., ZV-2) only supported FcgRII-mediated infection at high concentrations (Figure 2C ). Reciprocally, as described previously for WNV antibodies (Pierson et al., 2007) , the most inhibitory anti-ZIKV mAbs (ZV-54 and ZV-67) exhibited ADE, but this occurred only at sub-neutralizing concentrations. These experiments also corroborated the type-specificity of the mAbs, as only ZV-13 supported ADE of DENV. This latter observation suggests that at least some ZIKV-specific antibodies generated during natural infection can enhance DENV infection in vitro.
Structures of ZIKV Antibodies in Complex with DIII
To gain insight into the basis for differential binding and neutralization of the ZIKV mAbs, we generated Fab fragments or scFvs and undertook crystal screening using DIII of ZIKV H/PF/2013. X-ray crystal structures were obtained for four antibody complexes with DIII: ZV-2 Fab to 1.7-Å resolution, ZV-48 scFv to 1.7-Å resolution, ZV-64 Fab to 1.4-Å resolution, and ZV-67 Fab to 1.4-Å resolution ( Figure 3A ; data collection and refinement statistics in Table S1 and antibody-antigen structural analysis in Tables S2, S3 , and S4). In all four complexes, ZIKV DIII adopts a conserved structure nearly identical to that observed in soluble E dimers (Dai et al., 2016) as well as mature virions (Kostyuchenko et al., 2016; Sirohi et al., 2016) with variation observed primarily at the N-and C-terminal regions of the domain. Analysis of antibody contact residues indicates that ZV-2 and ZV-67 binding is dominated by heavy chain complementarity determining region (CDR) usage, whereas ZV-48 and ZV-64, which appear to be siblings and engage DIII in a similar manner, primarily use light-chain CDRs (Table S2 , S3, and S4; Figure S2 ). Notably, 10 of 12 light chain CDR contact residues are identical in ZV-48 and ZV-64, whereas only 2 of 11 heavy-chain CDR residues are the same, with the most significant difference in the short CDR-H3 of ZV-48 that makes more contact with DIII than the long CDR-H3 found in ZV-64 ( Figures 3A and S2) . Comparison of the sequences of ZV-67 with ZV-54, for the latter of which we lack structural data, suggests that they bind DIII very similarly, (B) Docking of the ZV-2, ZV-48, and ZV-64 complexes onto ZV-67-DIII. DIII is rendered as a molecular surface with each mAb contact surface color coded. Simultaneous docking of ZV-2 and ZV-67 with either ZV-48 or ZV-64 buries nearly half of the solvent surface of DIII and creates no van der Waal contacts between adjacent mAbs. (C) Five mAbs were probed for competitive and non-competitive binding against the DIII antigen by BLI. In one experiment, biotin-labeled ZV-67 was captured on the streptavidin sensor, the antibody was then loaded with ZIKV DIII followed by either ZV-54 or ZV-64, and finally, ZV-2 was added. In another experiment, ZV-48 was immobilized and ZV-64 or ZV-67 was added after DIII followed by ZV-2. Additional BLI signal indicates an unoccupied epitope (non-competitor), whereas no binding indicates epitope blocking (competition). In this experiment, ZV-48 competed with ZIKV-64 as expected given that they both bind nearly identical epitopes, while ZV-67 competed with its presumed sibling clone ZV-54. A dash (-) represents that no 2 nd or 3 rd antibody was offered.
See also Figure S2 and Tables S1, S2 , S3, and S4.
as only two contact residues differ, CDR-L3 Tyr/Phe L96 and CDR-H1 Ser/Thr H31 .
ZIKV mAbs Bind Three Spatially Distinct Epitopes on DIII
Analysis of the docking of our mAbs onto DIII indicates that ZV-2 and ZV-67 binding should not compete with ZV-48 or ZV-64 binding, whereas ZV-48 and ZV-64 should compete with each other ( Figure 3B ). To evaluate this prediction experimentally, we set up a competitive BLI assay ( Figure 3C ). When ZV-67 was immobilized, we observed that both ZV-64 and ZV-2 could bind in a DIII-dependent manner. In contrast, ZV-54 binding was excluded, supporting the idea that ZV-67 and ZV-54 recognize the same DIII determinants. Analogously, immobilized ZV-48 allowed for the binding of ZV-67 and ZV-2 after DIII capture, but ZV-64 was blocked competitively. This analysis strongly supports our structural observations and defines three distinct ZIKV type-specific epitopes on DIII.
ZIKV DIII Epitope Mapping
We examined the precise footprints of our mAbs on ZIKV DIII ( Figure 4A and 4B). ZV-2 binds to a large, fairly flat surface on the exposed face of the ABDE b sheet of DIII (Table S2 ). The ABDE sheet epitope is highly conserved among ZIKV sequences but many of the primary contacts diverge in other flaviviruses. Previous structural studies of the DENV cross-reactive mAb 2H12 revealed that it contacts six of the same residue positions, especially near the A-B loop (Midgley et al., 2012) . ZV-48 and ZV-64 both engage the C-and C 0 -b strands and connecting loop, which project away from the b sandwich core of DIII. The C-C 0 loop epitope recognized by ZV-48 and ZV-64 is remarkably similar to that engaged by the DENV-1 type-specific antibody E111 (Austin et al., 2012) , with 9 structurally related positions contacted ( Figure 4A ). The epitope recognized by ZV-67 is created by four discrete secondary structure elements: the A-strand, B-C loop, D-E loop, and F-G loop. A total of 21 residues are contacted by ZV-67, with only one difference between the two ZIKV immunizing strains (E E393 in H/PF/2013, D E393 in MR-766). This epitope region has been termed the LR and was described in relation to the binding of the potently neutralizing E16 mAb to WNV DIII . Notably, 13 contact positions of E16 and WNV DIII are shared by ZV-67 ( Figure 4A ). DV1-E106 is another mAb recognizing the LR-epitope (Edeling et al., 2014) , and it shares 10 contact positions with ZV-67, four of which are conserved in the B-C loops of WNV and ZIKV. Another related DIII epitope (termed the A-strand) has been described for two DENV-complex-specific mAbs, 1A1D-2 (Lok et al., 2008) and 4E11 (Cockburn et al., 2012) (Figure 4A ). These A-strand epitope binding mAbs do not make significant contact with the B-C or F-G loop residues engaged by LR-epitope mAbs. Collectively, the three distinct ABDE sheet, C-C 0 loop, and LR epitopes recognized by our mAbs represent nearly one half of the total ZIKV DIII surface area with no overlap in the contact residues.
Exposed and Cryptic ZIKV Epitopes
We docked our mAb-DIII structures onto the cryoelectron microscopy (cryo-EM)-derived model of the mature ZIKV virion (Kostyuchenko et al., 2016; Sirohi et al., 2016) . Whereas the LR epitope for ZV-67 was accessible on the mature virion (Figure 5A ), the C-C 0 loop and ABDE sheet epitopes were occluded almost completely in all three symmetry environments. We next examined the exposure of the ABDE sheet epitope on the E ectodomain crystal structure (Dai et al., 2016) and found that Fab binding is blocked sterically due to the adjacent positioning of DI ( Figure 5B ). Furthermore, dimerization of E would preclude ZV-2 mAb binding as its CDR loops contact several of the same DIII residues that are contacted by DII residues in the dimer. Examination of the binding of ZV-64 reveals that it likely engages the cryptic C-C 0 loop epitope in a manner similar to the DENV-1 specific mAb DV1-E111 (Austin et al., 2012) (Figures  5C and 5D) . Residues on the C-C 0 loop are intimately involved in lateral E protein contacts on the mature virion, so their exposure would require substantial reorganization of the particle, which perhaps could occur locally rather than globally. Our most potent mAbs, ZV-67 and ZV-54, recognize the LR epitope in a manner similar to WNV-E16, which can bind up to 120 of the 180 copies of DIII on the mature virion (Kaufmann et al., 2006; Nybakken et al., 2005) (Figures 5C and 5E ). This is the same stoichiometry observed for the binding of the A-strand-specific mAb 1A1D-2 Figure 5 . Accessibility of ZIKV DIII Epitopes (A) Mapping of the three distinct ZIKV DIII epitopes onto the mature virion (5IRE) (Sirohi et al., 2016) . The surface distribution of the ABDE sheet (green), C-C 0 loop (cyan), and LR (magenta) epitopes are rendered on the three symmetrically unique E proteins colored olive, wheat, and gray. While the ABDE sheet and C-C 0 loop epitopes are dominantly buried in all three symmetry environments, the LR epitope is solvent accessible on the mature virion.
(B) Docking of the ZV-2-DIII complex onto the crystal structure of dimeric ZIKV (5JHM) (Dai et al., 2016) . Shown above is the ZV-2 Fab docked to a soluble E monomer, which indicates that the ABDE sheet epitope is occluded by DI with clashes by the V H domain. Below, the ZIKV dimer is depicted, showing how it would sterically clash with the ZV-2 V L domain. ZV-2 CDR loops contact several of the same DIII residues that are contacted by the DII fusion loop in the dimer. (Lok et al., 2008) and DV4-4E11 scFv-DIII complex (Cockburn et al., 2012 ) onto the exposed A-strand epitope. (Lok et al., 2008) , which like 4E11 (Cockburn et al., 2012) , can broadly neutralize multiple DENV serotypes ( Figure 5F ). The clustering of DIII LR epitopes around the 5-fold axis of symmetry appears to preclude binding at this site ( Figure 5A ), although minor repacking of the interface could lead to possible binding (Edeling et al., 2014) .
In Vivo Protection Studies
Recently, we and others have generated in vivo models of ZIKV pathogenesis in mice deficient in type I IFN signaling Rossi et al., 2016) . To evaluate whether neutralizing mAbs protected against ZIKV infection in vivo, we treated 4-to 5-week-old WT C57BL/6 mice at day À1 with anti-Ifnar (2 mg) and anti-ZIKV or isotype control mAbs (250 mg) and then infected animals at day 0 with an African ZIKV strain that is more pathogenic in mice than isolates from Asia or the Americas . Treatment of mice with anti-Ifnar mAb and a non-binding isotype control mAb (CHIKV-166) resulted in high levels of ZIKV RNA in serum at day 3 ( Figure 6A ) and significant weight loss and mortality ( Figures 6B and 6C ). In comparison, treatment with anti-Ifnar mAb and the DIII LR mAbs ZIKV-54 or ZIKV-67 resulted in reduced viremia and complete clinical protection. Consistent with a recent vaccine study that showed antibody-mediated protection against ZIKV viremia in BALB/c mice (Larocca et al., 2016) , our neutralizing anti-ZIKV mAbs can protect against lethal ZIKV infection in IFN-deficient C57BL/6 mice. This model is a stringent test of protection, since in humans, the overwhelming majority of infections does not result in lethality.
DISCUSSION
We set out to develop a panel of mAbs against ZIKV that could provide insight into epitopes that are recognized by neutralizing antibodies. After inoculating mice with infectious ZIKV, we generated and characterized a panel of ZIKV-specific mAbs at both the functional and structural level. Four of the mAbs were ZIKV specific, bound to sites within DIII, and neutralized infection of a contemporary Asian strain of ZIKV. Whereas ZV-54 and ZV-67 neutralized other ZIKV strains efficiently, ZV-48 and ZV-64 showed reduced inhibitory activity against American and African ZIKV strains. Sequence analysis of the V L region of ZV-48 and ZV-64 suggest they are sibling clones, although the V H domains of the IgG heavy chains are distinct and make little contact with DIII. In comparison, the functionally related ZV-54 and ZV-67 mAbs have highly similar V L and V H sequences ( Figure S2 ). From these analyses, we defined three spatially distinct typespecific epitopes on ZIKV DIII (LR, C-C 0 loop, and ABDE sheet) with functionally different properties. Finally, in vivo passive transfer studies revealed protective activity of ZV-54 and ZV-67 against an African ZIKV strain in a lethal challenge model in mice.
Type-specific protective and neutralizing mAbs in DIII have been observed in studies with other flaviviruses. As no other ZIKV-specific mAbs have been described to date, it remains uncertain whether the DIII epitopes reported here are immunodominant in humans. However, antibodies to DIII, which is prominently displayed on the surface of flaviviruses (Pierson and Diamond, 2013) , appear less dominant in the human response against other flaviviruses (Beltramello et al., 2010; Jarmer et al., 2014; Smith et al., 2013) . The structures of three other antibodies with reactivity against ZIKV have been published recently. Dai et al. (2016) described the 3.0-Å structure of ZIKV E protein in complex with a cross-reactive murine antibody, 2A10G6. This antibody bound the highly conserved FL in DII and was poorly neutralizing (PRNT 50 of 249 mg/mL) yet still protected mice against lethal ZIKV infection. ZV-13 had a similar neutralizing profile in vitro and also bound to a DII-FL epitope. Barba-Spaeth et al. (2016) reported 2.4-Å and 2.6-Å structures of ZIKV E protein complexed with Fab fragments of C8 or A11 antibodies, both of which recognize EDE dimer epitopes (Rouvinski et al., 2015) . Although these cross-reactive anti-DENV antibodies inhibited ZIKV infection efficiently (FRNT 50 of $14 and 135 ng/mL, respectively, against H/PF/2013), no protection experiments with C8 or A11 and ZIKV were undertaken in animals.
Three of our mAbs recognized cryptic epitopes in the ABDE sheet (ZV-2) and C-C 0 loop (ZV-48 and ZV-64) on DIII, which are not predicted to be accessible on the mature virion (Kostyuchenko et al., 2016; Sirohi et al., 2016) . So how were these antibodies generated in vivo? ZV-48 and ZV-64 were the product of serial infections with two different strains of ZIKV (MR-766 and H/PF/2013) and a final 3-day boost with purified DIII prior to fusion and hybridoma generation. While it is possible that Daily weights were measured. For (A) and (B), statistical significance was analyzed by a one-way ANOVA with a Dunnett's multiple comparisons test (**p < 0.01; ***p < 0.001).
(C) ZV-54 and ZV-67 protected against ZIKV infection compared to the control CHK-166 mAb (***p < 0.001, log rank test). The results are pooled from two independent experiments with n = 8-9 mice for each treatment condition.
ZV-48 and ZV-64 were selected against the recombinant protein during the last boost, given the extensive somatic hypermutation seen in the sequences ( Figure S2 ), it seems more likely that viral breathing allows exposure of the C-C 0 loop, as observed previously for a neutralizing DENV-1 mAb (Austin et al., 2012) . For ZV-2, it is more difficult to comprehend, as this mAb was a product only of prime-boosts with infectious ZIKV MR-766 and H/PF/2013. Other possible ways to generate antibodies against cryptic epitopes include exposure of the epitope on partially mature viruses, SVPs, ''broken'' viral particles, or cleaved soluble envelope proteins.
The two mAbs (ZV-48 and ZV-64) that bound to the C-C 0 loop showed reduced neutralizing activity against the American and African strains. Sequence alignment of the C-C 0 loop contact residues in DIII of all four tested strains failed to reveal an explanation for the loss of inhibitory activity relative to the Asian H/PF/ 2013 ZIKV strain. Only a single amino acid change (A343V) in the crystallographic footprint was identified in MR-766 and Dakar 41671, and this substitution was not present in the Paraiba, 2015 sequence. This phenotype is similar to a neutralizing mAb (DV1-E111) that bound the C-C 0 loop of DENV-1 DIII, in which we observed a genotype-dependent pattern of neutralization (Austin et al., 2012 ) that mapped to a single conservative amino acid substitution in DII remote from the footprint of the epitope (Dowd et al., 2015) .
We observed protection in vivo by DIII LR neutralizing mAbs (ZV-54 and ZV-67). This result is similar to that observed for other DIII LR mAbs against flaviviruses that protected against lethal infection by WNV , DENV-1 (Shrestha et al., 2010 ), or DENV-2 (Sukupolvi-Petty et al., 2010 . Although mechanistic studies with ZV-54 and ZV-67 remain to be performed, protective mAbs against WNV and DENV that bound the DIII LR epitope inhibited infection at a post-attachment stage including blocking viral fusion from the endosome (Thompson et al., 2009) .
A key question remains whether neutralizing antibodies will protect pregnant women and their developing fetuses from ZIKV infection and congenital malformations, including microcephaly. Although we and others have developed models of infection of pregnant mice with resultant injury to the fetus (Cugola et al., 2016; Miner et al., 2016) , we chose not to perform such protection studies because mice, in contrast to many other mammalian species, lack expression of the neonatal Fc receptor (FcRn) on their trophoblasts in the chorioallantoic placenta (Kim et al., 2009) . Rather, FcRn is expressed in the mouse yolk sac endoderm, and thus, the transfer of IgG in mice is believed to be predominantly postnatal (Pentsuk and van der Laan, 2009 ). As reduced levels of transport of maternal or exogenous IgG into the fetus occur in mice, protection by a given antibody may be underestimated. Passive antibody transfer studies during pregnancy may require experiments in mammals with more similar placental anatomy that are susceptible to ZIKV infection (e.g., nonhuman primates).
Our studies identify ZIKV DIII as a potential target of neutralizing antibodies and thus a possible immunogen for vaccines. DIII has been used previously in the context of different flavivirus vaccines (Martina et al., 2008; Schneeweiss et al., 2011) . Although neutralizing antibodies are generated in several animal species in response to soluble DIII immunogens, the titers have been lower than expected, possibly because of immunodominance of regions of DIII that normally are inaccessible on the viral particle. Alternatively, the mouse V H -CDR3 regions are shorter and vary in amino acid composition compared to other species (Shi et al., 2014) , which could impact immundominance against DIII epitopes in a species-specific manner. Our structural analysis provides a hierarchy of neutralization efficacy associated with distinct epitopes on DIII. Masking of epitopes that fail to elicit neutralizing antibodies could be combined with epitope-focused vaccine design approaches (Correia et al., 2014) to generate DIII variants that induce more protective responses.
In summary, we identified a panel of type-specific ZIKV mAbs, several of which bind to distinct regions on DIII and have disparate functional activities. Type-specific anti-ZIKV mAbs could be useful for diagnostic assays that distinguish ZIKV antigens from closely related flaviviruses, including DENV. Alternatively, their characterization may provide a path forward for developing prophylactic antibodies for use in pregnancy, for therapeutic antibodies to potentially prevent viral persistence, or for the design of domain and minimal epitope-specific vaccines against ZIKV infection.
EXPERIMENTAL PROCEDURES Ethics Statement
This study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the NIH. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine.
Viruses
ZIKV strain H/PF/2013 (French Polynesia, 2013) was obtained from X. de Lamballerie (Aix Marseille Université ). ZIKV Brazil Paraiba 2015 was provided by S. Whitehead (Bethesda) and originally obtained from P.F.C. Vasconcelos (Instituto Evandro Chagas). ZIKV MR-766 (Uganda, 1947) and Dakar 41519 (Senegal, 1982) were provided by the World Reference Center for Emerging Viruses and Arboviruses (R. Tesh, University of Texas Medical Branch). Nicaraguan DENV strains (DENV-1 1254-4, DENV-2 172-08, DENV-3 N2845-09, and DENV-4 N703-99) were generously provided by E. Harris (University of California, Berkeley). Virus stocks were propagated in C6/36 Aedes albopictus cells . ZIKV Dakar 41519 was passaged in vivo in Rag1 À/À mice (M.J.G. and M.S.D., unpublished data) and a brain homogenate was used. Virus stocks were titrated by focus-forming assay (FFA) on Vero cells as described . 
ZIKV mAb Domain Mapping by ELISA
A MAXISORP 96-well plate (Nunc) was coated with 50 mL of 2 mg/mL of recombinant ZIKV E, ZIKV E-FL (fusion-loop mutant), ZIKV DIII, WNV-E, or DV4-E overnight at 4 C. Plates were washed three times with PBS with 0.02% Tween 20 followed by incubation with PBS, 2% BSA, and 0.02% Tween 20 for 1 hr at 37 C. MAbs (0.5 mg/mL) were added for 1 hr at room temperature.
Plates were washed again and then sequentially incubated with 2 mg/mL of HRP-conjugated anti-mouse IgG and tetramethylbenzidine substrate. The reaction was stopped by the addition of 1 N H 2 SO 4 to the medium, and emission (450 nm) was read using an iMark microplate reader (Bio-Rad). [Pal et al., 2013] ; positive, WNV E53 [Oliphant et al., 2006] ). After washing, cells were incubated with an Alexa Fluor 647-conjugated goat anti-mouse IgG (Invitrogen), fixed in 1% PFA in PBS, processed on a FACS Array (BD Biosciences), and analyzed using FlowJo software (Tree Star).
Neutralization Assays
Biolayer Interferometry Binding Assays
The binding affinity of purified ZIKV E or ZIKV DIII protein with ZIKV mAbs was monitored by BLI using an Octet-Red96 device (Pall ForteBio). Briefly, 100 mg of each antibody was mixed with biotin (EZ-Link-NHS-PEG4-Biotin, Thermo Fisher) at a molar ratio of 20:1 biotin:protein and incubated at room temperature for 30 min. The unreacted biotin was removed by passage through a desalting column (5 mL Zeba Spin 7K MWCO, Thermo Fisher). The antibodies were loaded onto streptavidin biosensors (ForteBio) until saturation, typically 2 mg/mL for 3 min, in 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, and 0.005% P20 surfactant with 3% BSA. Association and dissociation were measured at 25 C for all mAbs. The real-time data were analyzed using Biaevaluation 4.1 (GE Healthcare). Association and dissociation profiles, as well as steady-state equilibrium concentration curves, were fitted using a 1:1 binding model.
SVP Production and Binding Assay
ZIKV SVPs were generated as described previously for WNV (Hanna et al., 2005) . Briefly, a plasmid encoding the prM-E gene of ZIKV H/PF/2013 was transfected into HEK293T cells. SVPs were harvested every 24 hr and stored aliquoted at À80 C. 96-well high-binding plates (Immulon 4HBX; Thermo Scientific) were coated with 1 mg/mL of ZV-67 in coating buffer (15 mM sodium carbonate, 35 mM sodium bicarbonate [pH 9.6]) overnight at 4 C. Plates were blocked with PBS-T + 1.5% BSA, followed by capture of SVPs diluted in blocking buffer for 1 hr at 37 C. Plates were incubated with the indicated concentrations of biotin-conjugated mAbs for 30 min at 37 C, followed by incubation with 30 ng/mL streptavidin-HRP for 30 min at 37 C. The plates were developed with SureBlue TMB substrate (KPL) and stopped with 1 M HCl.
Plates were analyzed at 450 nm, with a 570 nm correction (BioTek).
ADE Studies
RVP production and ADE assays were performed using approaches detailed in prior studies with WNV and DENV RVPs Pierson et al., 2007) using plasmids expressing the C-prM-E genes of ZIKV H/PF/2013 or DENV-2 16681 and a plasmid encoding a WNV replicon expressing GFP. Infection of human K562 cells were carried out at 37 C and GFP-positive infected cells were detected by flow cytometry 48 hr later.
Mouse Protection Experiments C57BL/6 mice (4-to 5-week-old, Jackson Laboratories) were inoculated with ZIKV by subcutaneous (footpad) route with 10 5 FFU of mouse-adapted ZIKV Dakar in a volume of 50 mL. One day prior, mice were treated with 2 mg of an Ifnarblocking mAb (MAR1-5A3) by intraperitoneal injection . ZIKV mAbs were administered as a single 250 ug dose 1 day before infection via an intraperitoneal route. Serum samples were obtained at day 3 after ZIKV infection and extracted with the Viral RNA Mini Kit (QIAGEN). ZIKV RNA levels were determined by TaqMan one-step qRT-PCR on an ABI 7500 Fast Instrument using published primers and conditions (Lanciotti et al., 2008) .
Statistical Analysis
All virological data were analyzed with GraphPad Prism software. Kaplan-Meier survival curves were analyzed by the log rank test, and weight losses and viremia were compared using an ANOVA with a multiple comparisons test. A p value of <0.05 indicated statistically significant differences. SVP ELISA data were analyzed by non-linear regression analysis using a one-site binding model.
Protein Production, Purification, and Crystallization
This section is described in the Supplemental Experimental Procedures.
Structure Determination, Refinement, and Analysis This section is described in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The accession numbers for the crystal structures of ZIKV DIII complexed with ZV-2 Fab, ZV-48 scFv, ZV-64 Fab, and ZV-67 Fab are RCSB: 5KVD, 5KVE, 5KVF, and 5KVG, respectively. 
SUPPLEMENTAL INFORMATION
